FDA Breakthrough Designation Generates Big Meetings, Big Results, Scioderm Says
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biotech start-up met with 22 agency officials to discuss development of its compound for treatment of epidermolysis bullosa, a rare, genetic connective tissue disorder.